Pharvaris (PHVS) Competitors $21.66 +0.70 (+3.34%) As of 03:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHVS vs. ACLX, KYMR, PTGX, CRNX, ZLAB, AKRO, ACAD, AAPG, MIRM, and LNTHShould you be buying Pharvaris stock or one of its competitors? The main competitors of Pharvaris include Arcellx (ACLX), Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), Zai Lab (ZLAB), Akero Therapeutics (AKRO), ACADIA Pharmaceuticals (ACAD), Ascentage Pharma Group International (AAPG), Mirum Pharmaceuticals (MIRM), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. Pharvaris vs. Its Competitors Arcellx Kymera Therapeutics Protagonist Therapeutics Crinetics Pharmaceuticals Zai Lab Akero Therapeutics ACADIA Pharmaceuticals Ascentage Pharma Group International Mirum Pharmaceuticals Lantheus Arcellx (NASDAQ:ACLX) and Pharvaris (NASDAQ:PHVS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation. Which has more risk & volatility, ACLX or PHVS? Arcellx has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500. Comparatively, Pharvaris has a beta of -2.77, meaning that its share price is 377% less volatile than the S&P 500. Do analysts recommend ACLX or PHVS? Arcellx currently has a consensus target price of $112.69, indicating a potential upside of 22.94%. Pharvaris has a consensus target price of $37.17, indicating a potential upside of 71.59%. Given Pharvaris' higher possible upside, analysts plainly believe Pharvaris is more favorable than Arcellx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcellx 1 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.87Pharvaris 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has preferable valuation & earnings, ACLX or PHVS? Arcellx has higher revenue and earnings than Pharvaris. Arcellx is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcellx$56.98M89.22-$107.35M-$3.42-26.80PharvarisN/AN/A-$145.24M-$3.36-6.45 Do insiders & institutionals have more ownership in ACLX or PHVS? 96.0% of Arcellx shares are owned by institutional investors. 8.4% of Arcellx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media refer more to ACLX or PHVS? In the previous week, Pharvaris had 2 more articles in the media than Arcellx. MarketBeat recorded 12 mentions for Pharvaris and 10 mentions for Arcellx. Pharvaris' average media sentiment score of 0.78 beat Arcellx's score of 0.04 indicating that Pharvaris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcellx 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Pharvaris 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ACLX or PHVS more profitable? Pharvaris has a net margin of 0.00% compared to Arcellx's net margin of -329.93%. Arcellx's return on equity of -43.04% beat Pharvaris' return on equity.Company Net Margins Return on Equity Return on Assets Arcellx-329.93% -43.04% -27.41% Pharvaris N/A -69.09%-63.34% SummaryArcellx beats Pharvaris on 10 of the 16 factors compared between the two stocks. Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHVS vs. The Competition Export to ExcelMetricPharvarisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.13B$3.40B$6.05B$10.51BDividend YieldN/A2.30%5.73%4.80%P/E Ratio-6.4523.0384.9327.30Price / SalesN/A268.08515.79197.96Price / CashN/A46.9537.5761.53Price / Book3.9110.5412.426.82Net Income-$145.24M-$52.58M$3.32B$276.59M7 Day Performance-5.74%0.59%0.53%0.00%1 Month Performance-7.36%15.50%10.24%7.96%1 Year Performance4.03%18.01%75.92%35.10% Pharvaris Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHVSPharvaris2.7474 of 5 stars$21.66+3.3%$37.17+71.6%+1.9%$1.13BN/A-6.4530News CoverageAnalyst ForecastGap UpHigh Trading VolumeACLXArcellx2.0028 of 5 stars$84.38-0.8%$114.31+35.5%+0.6%$4.72B$107.94M-24.6780Analyst RevisionKYMRKymera Therapeutics1.344 of 5 stars$57.55-0.6%$61.26+6.5%+26.5%$4.14B$47.07M-16.58170Insider TradePTGXProtagonist Therapeutics1.6843 of 5 stars$64.14-1.1%$68.36+6.6%+66.0%$4.03B$209.18M91.63120Analyst ForecastInsider TradeGap DownCRNXCrinetics Pharmaceuticals3.7504 of 5 stars$41.68+2.0%$74.45+78.6%-17.0%$3.85B$1.04M-10.14210ZLABZai Lab2.7795 of 5 stars$33.31-1.3%$56.35+69.2%+18.9%$3.77B$398.99M-16.331,869News CoveragePositive NewsAKROAkero Therapeutics3.6892 of 5 stars$46.04-0.1%$81.14+76.2%+79.3%$3.69BN/A-23.0230Insider TradeACADACADIA Pharmaceuticals4.5116 of 5 stars$21.59-1.0%$29.12+34.9%+35.8%$3.68B$1.02B16.23510Analyst ForecastAAPGAscentage Pharma Group InternationalN/A$39.86+1.2%N/AN/A$3.67B$134.35M0.00600News CoverageGap UpMIRMMirum Pharmaceuticals3.172 of 5 stars$72.53-0.6%$76.50+5.5%+84.3%$3.66B$336.89M-59.94140Positive NewsLNTHLantheus4.5688 of 5 stars$52.70-2.1%$85.50+62.2%-50.3%$3.66B$1.53B14.02700Analyst Revision Related Companies and Tools Related Companies Arcellx Alternatives Kymera Therapeutics Alternatives Protagonist Therapeutics Alternatives Crinetics Pharmaceuticals Alternatives Zai Lab Alternatives Akero Therapeutics Alternatives ACADIA Pharmaceuticals Alternatives Ascentage Pharma Group International Alternatives Mirum Pharmaceuticals Alternatives Lantheus Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHVS) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharvaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
